BioSpace News Archive

This decision brings PrMAVENCLAD® (cladribine tablets) closer to broader access for eligible patients living with Relapsing-Remitting Multiple Sclerosis in the province of Quebec

The National Council on Aging announced it has retained Spencer Stuart, the global executive search and leadership advisory firm, to lead a national search for its next President and CEO.

ALK Positive (a patient-led group of 1,900+ lung cancer patients and caregivers in 50+ countries) and GO2 Foundation for Lung Cancer (a global lung cancer advocacy and education organization) are awarding a two-year, $500,000 Research Collaboration Grant to two renowned lung cancer researchers dedicated to overcoming treatment resistance.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced the closing of its previously announced registered direct offering of 197,056 shares of common stock, at a purchase price of $8.83 per share, priced at-the-market under Nasdaq rules

We are very pleased to announce that Rosa Canet-Avilés, Ph.D., has joined The Association for Frontotemporal Degeneration as our first Senior Director of Scientific Initiatives.

Health Canada recently tested a number of USB wall chargers intended for use with cell phones, tablets and other devices as part of a planned national compliance and enforcement project.

Plus Therapeutics, Inc., announced that Andrew J. Sims has been appointed as the company’s Chief Financial Officer, effective February 5, 2020.

Plus Therapeutics, Inc., announced that Greg B. Petersen has joined the Company’s Board of Directors to serve as an independent director, effective February 14, 2020. Greg will serve on the Audit and Compensation Committees.

ADMA Biologics, Inc. announced the pricing of its previously announced underwritten public offering of 23,500,000 shares of its common stock at a public offering price of $3.50 per share, resulting in gross proceeds of approximately $82.3 million before deducting underwriting discounts and commissions and other estimated offering expenses..

Onkos Surgical® is pleased to announce the launch of GenVie™ Magnesium Bone Scaffold, a novel biologic technology that further expands Onkos’ reach in complex limb salvage procedures.